RPL stock case: SC dismisses SEBI's appeal against SAT order giving relief to Mukesh Ambani
The Hindu
Supreme Court dismisses SEBI plea against SAT order on RIL chairman Mukesh Ambani in 2023 trading case.
The Supreme Court on Monday (November 11, 2024) dismissed a plea filed by SEBI against a Securities Appellate Tribunal order which set aside the penalty imposed by the market regulator on RIL chairman Mukesh Ambani and two other entities in a case related to alleged manipulative trading in shares of the erstwhile Reliance Petroleum Ltd (RPL) in November 2007.
A bench of Justices J B Pardiwala and R Mahadevan said it was not inclined to interfere with the order passed by SAT.
"Impugned order was passed in 2023 which was challenged in 2023 and after one year, now the matter is being circulated.
"No question of law involved in this appeal warranting our interference. Dismissed. You can't chase a person like this for years," the bench said.
SEBI had moved the top court against the December 4, 2023, order of the Securities Appellate Tribunal (SAT).
The SAT ruling came after all the entities appealed before the tribunal against the order passed by the Securities and Exchange Board of India (Sebi) in January 2021.
In January 2021, SEBI imposed a ₹25 crore fine on Reliance Industries Ltd (RIL), ₹15 crore on Ambani, who is the company's Chairman and Managing Director, ₹20 crore on Navi Mumbai SEZ Pvt Ltd and ₹10 crore on Mumbai SEZ Ltd in the RPL case.
Equity markets decline on weak earnings, global trends; inflation hits 14-month high, foreign funds exit, oil prices rise.
Swiggy IPO debuts with a 7.69% jump at NSE, market valuation at ₹89,549.08 crore; shares listed at ₹412 on BSE.
Shares in Samsung Electronics fell on Wednesday to their lowest level in more than four years.
Mercedes-Benz India introduces the new Mercedes-AMG C 63 S E Performance sportscar with hybrid powertrain and innovative business model.
Hyundai Motor India Ltd. reports 16% profit decline in Q3 due to market sentiments, geopolitical factors, and Red Sea crisis.
Equity market plunges over 800 points, eroding market capitalisation by ₹5.29 lakh crore amid global economic concerns.
Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three products.
BCCI to withdraw insolvency plea against Byju's after Supreme Court sets aside NCLAT judgement, NCLT hearing scheduled.
Natco Pharma's Q2 profits soar 83% to ₹676.5 crore, driven by robust exports and stable domestic business.
India's industrial output rebounds with 3.1% growth in September, led by manufacturing, despite weak electricity and mining sectors.
India's retail inflation hits 6.2% in October, driven by a 10.9% spike in food prices, breaching RBI's upper limit.